← Leaderboards
Susan Creary
Emory University
$2,068,115
Attributed
$4,068,519
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,068,519 · 5
By mechanism
R44$1,904,006 · 1
R01$794,661 · 1
K23$758,903 · 1
R21$459,079 · 1
R03$151,870 · 1
Top collaborators
- Darryl Brice Hood3 shared
- Benjamin T Kopp3 shared
- Asuncion Mejias3 shared
- Sebastian Seiguer3 shared
- Octavio Ramilo2 shared
- Matthew Z Anderson1 shared
- Gregory C. Gibson1 shared
- Vivien Andrea Sheehan1 shared
Most similar at Emory University
Same institution · by research overlap
- Dean P. Jones$29,823,845
- Carmen Joseph Marsit$32,367,089
- Anne Lang Dunlop$11,135,883
- Edward T Morgan$16,635,008
- Sandra B. Dunbar$10,524,522
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicSickle Cell AnemiaChildHematological DiseaseParticipantCaringDesignHigh RiskMorbidity - Disease RateAffectHydroxyureaFundingInnovationNational Heart, Lung, And Blood InstituteAdherenceMortalityPublic HealthImproved OutcomePainFeedbackClinical TrialsClinical PracticeDirectly Observed TherapyInherited
Grant awards (13)
SMILE (Sickle Cell Disease Microbiologic and Immunologic Links to Health)$794,661
R01 · FY2025 · HL
ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$649,256
R44 · FY2025 · HL
ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$611,906
R44 · FY2024 · HL
SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity$236,634
R21 · FY2024 · AI
ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$642,844
R44 · FY2023 · HL
SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity$222,445
R21 · FY2023 · AI
SCTaware: A Comprehensive Program to Increase Sickle Cell Trait Knowledge and Awareness Among Parents of Infants Identified by Newborn Screening$76,000
R03 · FY2020 · HL · contact PI
A multidimensional strategy to improve hydroxyurea adherence in children with sickle cell$156,476
K23 · FY2019 · HL · contact PI
SCTaware: A Comprehensive Program to Increase Sickle Cell Trait Knowledge and Awareness Among Parents of Infants Identified by Newborn Screening$75,870
R03 · FY2019 · HL · contact PI
A multidimensional strategy to improve hydroxyurea adherence in children with sickle cell$158,765
K23 · FY2018 · HL · contact PI
A multidimensional strategy to improve hydroxyurea adherence in children with sickle cell$157,107
K23 · FY2017 · HL · contact PI
A multidimensional strategy to improve hydroxyurea adherence in children with sickle cell$158,948
K23 · FY2016 · HL · contact PI
A multidimensional strategy to improve hydroxyurea adherence in children with sickle cell$127,607
K23 · FY2015 · HL · contact PI